226 patients with metastatic breast cancer have been enrolled in the AIPAC study Combination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with chemotherapy is designed to boost the T-cell immune responses against...
Accordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson’s disease patients Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that results from an earlier...
Global pharmaceutical company expands use of Medidata Rave Clinical Cloud™ to spur growth and innovation Agreement builds on long-standing relationship since 2006 Unified platform approach creates a single source of truth for greater efficiency and accelerated trials...
—Researchers Report Substantial Oxalate Reduction Following Single-Dose Administration of DCR-PHXC in Additional Patients with PH2— —Enrollment Underway in Pivotal PHYOX2 Trial of DCR-PHXC— CAMBRIDGE, MA, USA I June 21, 2019 I DicernaTM Pharmaceuticals, Inc. (Nasdaq:...
MEI Pharma, Inc. (NASDAQ:MEIP ), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced that updated data presented in an oral presentation at ICML 2019 from a Phase 1b study of investigational ME-401, a selective...
Email
Text